Psicosis Asociada a Alzheimer

Estado: Reclutando

A study to sssess efficacy and safety of KarXT for the treatment of psychosis associated with alzheimer’s disease (ADEPT-2).

Para inscribirte contáctate a: [email protected]

Principales Criterios de Inclusión:

  • Must have completed study CN012-0026 or CN012-0027.
  • Subject was aged 55 to 90 years, inclusive, at the time of enrollment into the parent CN012-0026 or CN012-0027 study.
  • Can understand the nature of the study and protocol requirements and provide a signed informed consent or, if deemed not competent to provide informed consent, provide assent and the subject’s legally acceptable representative or study partner/caregiver, if local regulations allow, must provide informed consent before any study assessments are performed.
  • At entry into this study, or any time during the study, if a subject needs to relocate from home or residential assisted-living facility to a nursing home facility, the Sponsor/Medical Monitor must approve the subject’s participation in the study.
  • Have an identified or proxy caregiver (spends approximately 10 hours/week with the subject).
Ciudades con sitios abiertos a enrolamiento:
Santiago
  • Psicomed Estudios Clínicos

Consulta la Base de Datos
del Buscador de Ensayos Clínicos CIF

Si deseas conocer los datos de los Ensayos Clínicos en desarrollo, accede a nuestra base de datos que tenemos disponible aquí, con información actualizada trimestralmente.

Encuentra tu
ensayo clínico

Elige tu área de interés, patología o región, y accede a tu ensayo clínico.

Buscar ensayos >